Celebrating the discovery of mutated CALR
MPN Research Foundation is proud to celebrate the 10-year anniversary of the identification of CALR as a common driver of MPNs. We funded early work that discovered this MPN driver mutation. Learn more >
MPNRF by the numbers
Total donated dollars
invested in research
$ 0 M
Researchers supported
0
Countries with
supported research
0
Projects funded
0

What is
essential
thrombocythemia
(ET)
?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is
polycythemia vera
(PV)
?

Polycythemia vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

What is
myelofibrosis
(MF)
?

Myelofibrosis (MF)

MF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF
Patients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Connect with us to be part of our coordinated effort to find new treatments — and eventually cures — for MPNs.

Patients
and Caregivers

Every patient experience is unique and provides new clues for researchers and clinicians.

Researchers
and
Clinicians

In our 24-year history, MPNRF has contributed to some of the most influential MPN research discoveries.

Industry
and
Biopharma

Engage with us to ensure that new therapies have the maximum impact on patient outcomes and quality of life.

Download our Voice of the Patient report

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Stay connected

Invest in MPN research

Your investment supports doctors and researchers around the world who are dedicated to finding cures for MPNs.

 INVEST NOW

Join the community
Be the first to know about the latest news and advancements for ET, PV, and MF. Sign up to receive our newsletters and alerts.

Recent news

  • Need help with MPN related out-of-pocket expenses?

    MPN NEWS | June 25, 2024

    Need help with MPN related out of pocket expenses?   The PAN Foundation is helping patients with Philadelphia chromosome negative myeloproliferative neoplasms (MPN) afford their out-of-pocket costs. If you’re a patient or caregiver looking for resources to help with your treatment-related costs, we encourage you to learn more about the PAN Foundation and its $3,250 annual… Read More »Need help with MPN related out-of-pocket expenses?

    READ MORE

    MPN patient guidelines updated by NCCN  

    MPN NEWS | June 24, 2024

    To stay up to date on everything MPNs, patients and their families and caregivers have access to a just updated resource that includes 75 pages of plain language questions, answers, and explanations written specifically for people affected by MPNs. The comprehensive document is based on current clinical practice guidelines created by national leaders in the… Read More »MPN patient guidelines updated by NCCN  

    READ MORE

    Vikas Gupta, MD, FRCP, FRCPPath

    MPN NEWS | June 24, 2024

    Profile: Vikas Gupta, MD, FRCP, FRCPPath Princess Margaret Cancer Centre University Health Network, Toronto, Canada  How can we best study transplant vs best available non-transplant therapies in myelofibrosis patients? According to Dr. Vikas Gupta, studies have shown that high-risk myelofibrosis (MF) patients appear to have better survival with hematopoietic stem cell transplants (HCT) than with… Read More »Vikas Gupta, MD, FRCP, FRCPPath

    READ MORE